Jim Cramer Says Eli Lilly “Will Tell a Good Story When It Reports”

Eli Lilly and Company (NYSE:LLY) was on Jim Cramer’s Mad Money game plan for the week ahead. Noting that there is controversy around the company recently, Cramer said:

Now, this one’s a little controversial, Eli Lilly. They announced some scripts for the new weight loss drug, and they were disappointing. I admit that. Stock sold off big. I say, calm down. Lilly will tell a good story when it reports on Thursday morning. They’ve got a… little longer-term view than just 10 days.

Photo by Artem Podrez on Pexels

Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic conditions. When a caller asked if the stock is a buy, sell, or hold on March 18, Cramer replied:

Okay, everybody’s giving up on Lilly. My experience with Eli Lilly is there are bouts of giving up in this. That’s what I call it, giving up in this. We’re in a giving up in this moment for one of the greatest, if not the greatest, drug company in history. I think the pill is going to be gigantic. People are saying that the… GLP is not big, okay? Not as big as we thought… What can I say? Buy Eli Lilly.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.